Clinical trial • Phase I • Other
REGN22044 for Healthy volunteer
Phase I trial of REGN22044 for Healthy volunteer. 64 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 16-03-2026
- First CTIS Authorization Date
- 11-05-2026
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 64
Eligibility
Recruits 64 No vulnerable populations selected.
- Vulnerable Population
- No vulnerable populations selected
Recruitment
- Planned Sample Size
- 64
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 64
Belgium
- Earliest CTIS Part Ii Submission Date
- 04-05-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 7
- Number Of Sites
- 1
- Number Of Participants
- 64
Sites
- Site Name
- Universiteit Gent
- Department Name
- Drug Research Unit Ghent
- Contact Person Name
- Griet Van Lancker
- Contact Person Email
- griet.vanlancker@uzgent.be
Sponsor
Primary sponsor
- Full Name
- Regeneron Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- REGN22044
- First In Human
- Yes
Related trials
Other published trials that may interest you.